An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Histology--Hematopoietic: How is histology coded for a "chronic lymphocytic leukemia with plasmacytic differentiation"?
For cases diagnosed prior to 1/1/2010:Assign histology code 9823/3 [Chronic lymphocytic leukemia]. Plasmacytic differentiation does not indicate a plasma cell or plasmacytic leukemia.
For cases diagnosed 1/1/10 and later, refer to the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database (Hematopoietic DB) provided by SEER on its website to research your question. If those resources do not adequately address your issue, submit a new question to SINQ.
MP/H Rules/Histology--Breast: How is histology coded for a diagnosis of "metaplastic carcinoma with the sarcomatous component of high grade sarcoma with focal areas of osteoid formation"? See Discussion.
Right breast simple mastectomy, path: 2.5 x 1.5 x 1.5 cm metaplastic carcinoma with; the sarcomatous component is high grade sarcoma with focal areas of osteoid formation. The epithelial component is predominantly grade 2 DCIS.
For cases diagnosed 2007 or later, assign code 8575 [Metaplastic carcinoma, NOS]. Metaplastic carcinomas often include mixtures of epithelial carcinoma with sarcoma, for example.
Reportability--Appendix: Is a metastatic low-grade appendiceal mucinous neoplasm reportable if the pathologist states that it is a borderline tumor of the appendix? See Discussion.
Low-grade appendiceal mucinous neoplasm; Lt ovary, cul-de-sac, omentum, and small bowel: Metastatic low-grade appendiceal mucinous neoplasm. Per pathologist this is a borderline tumor of the appendix.
Borderline tumors (other than brain and CNS) are not reportable to SEER. In the case of borderline tumors, the term "metastatic" does not automatically make them reportable. When the "metastatic deposits" are also borderline, the case is not reportable. For this case in particular, the "metastases" are actually (benign) implants and not malignant or invasive mets.
MP/H Rules/Histology--Breast: How is histology coded for a breast primary with a final diagnosis of "infiltrating duct carcinoma with apocrine features"? See Discussion.
I & R has conflicting answers: #25719 (dated 3/17/2008) says per rule H12 this is 8401/3 but #23347 (dated 8/12/07) says per rule H16, this is 8523/3.
For cases diagnosed 2007 or later, assign histology code 8401/3 [apocrine adenocarcinoma] according to rule H12. Apocrine is a type of duct carcinoma, see table 1. Code 8401 should be listed in Rule H12. Apocrine should be removed from table 3.
These corrections will appear in the revised version of the rules.
Primary site--Colon: How do you determine the correct subsite when there is conflicting information in different reports? Are there priority rules for coding subsite for sites other than Head and Neck? See Discussion.
The path report for a hemicolectomy says, " Specimen: left colon..." and the microscopic says, "...received in formalin designated left colon..." The Operative procedure report says, "Postoperative diagnosis - splenic flexure tumor." The text of this report says, "Mobilizing the splenic flexure mass was incredibly difficult..." and then goes on to describe exactly how and where it was resected. The discharge summary says adenosquamous carcinoma of the splenic flexure. SINQ20051010 says to use the pathology report first, but this was written before the new MP/H rules.
Use the operative report information to code primary site in this case. It is more accurate.
The operative report is usually a better source of location information compared to the pathology report. The pathologist can only reiterate the location as it was reported to him/her.
The 2007 SEER manual states "Unless otherwise instructed, use all available information to code the site," page 69.
Grade/Cell indicator--Lymphoma: How is Grade/Cell indicator coded for anaplastic large cell lymphoma? See Discussion.
The SPCM states cell indicator codes take precedence over grade/differentiation codes for lymphoma and leukemia cases.
For cases diagnosed prior to 1/1/2010:Because there is no cell indicator information, code 9 [cell type not determined] in the grade/cell indicator field. Do not code grade for lymphoma. For lymphoma and leukemia this field is the cell indicator.
For cases diagnosed 1/1/10 and later, refer to the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database (Hematopoietic DB) provided by SEER on its website to research your question. If those resources do not adequately address your issue, submit a new question to SINQ.
Behavior--Breast: How is this field coded for a case in which the final diagnosis reports DCIS, but the CAP protocol or microscopic findings show microinvasion? See Discussion.
1. Path report for breast cancer has final diagnosis as 'DCIS' but the CAP protocol in the body of the report says 'microinvasion seen, T1mic.'
2. Path report says 'DCIS' in the final diagnosis and microinvasion is identified in the microscopic portion of the report, but it is not in CAP protocol format and not stated in the final diagnosis.
Code both scenarios /3 [malignant (invasive)]. Information regarding behavior is not limited to the final diagnosis or the CAP protocol. See page 84 in the 2007 SEER manual:
Code the behavior as malignant /3 if any portion of the primary tumor is invasive no matter how limited; i.e. microinvasion.
Reportability/Histology--Brain and CNS: Is an "inflammatory myofibroblastic tumor" reportable for Brain and CNS sites? See Discussion.
Histology code 8825/1 (Inflammatory Myofibroblastic Tumor) is not listed in the ICD-0-3 Primary Brain and CNS Site/Histology listing for reportable Brain/CNS tumors.
If the inflammatory myofibroblastic tumor is primary in one of the sites specified below and diagnosed 1/1/2004 or later, it is reportable.
Reportable brain and CNS tumors are any benign and borderline primary intracranial and CNS tumors with a behavior code of /0 or /1 in ICD-O-3 diagnosed 1/1/2004 and later, of the following sites:
Cerebral meninges C700
Spinal meninges C701
Meninges, NOS C709
Cerebrum C710
Frontal lobe C711
Temporal lobe C712
Parietal lobe C713
Occipital lobe C714
Ventricle, NOS C715
Cerebellum, NOS C716
Brain stem C717
Overlapping lesion of brain C718
Brain, NOS C719
Spinal cord C720
Cauda equine C721
Olfactory nerve C722
Optic nerve C723
Acoustic nerve C724
Cranial nerve, NOS C725
Overlapping lesion of brain and central nervous system C728
Primary site--Bladder: What is the correct subsite for "interureteric ridge"? See Discussion.
Description: 4 mm nodule at base of bladder near interureteric ridge.
For this case, assign code C670 [Trigone of bladder]. The description for this case states that the tumor location is the base of the bladder. Base is a synonym for trigone.
The interureteric ridge (or interureteric crest, or interureteric fold) is a fold of mucous membrane extending accross the bladder between the two ureteric orifices. The trigone is located below the interureteric ridge.
MP/H Rules/Multiple Primaries--Head & Neck: How many primaries should be reported when an invasive squamous cell carcinoma of the right mandibular body (C06.9) was diagnosed in 2004 (treated with surgery and radical neck dissection), and an invasive squamous cell carcinoma of the left buccal mucosa (C06.0) was diagnosed in 2007? See Discussion.
According to the MP/H Rules, it appears Rule M12 would apply since none of the others fit and these would be a single primary.
For cases diagnosed 2007-2014:
Based on the information provided, the primary site code for the 2004 primary should be C031 [mandibular gingiva, lower alveolar mucosa, etc.].
The 2007 diagnosis would be a separate primary according to rule M7 because the patient was disease free following treatment for the 2004 diagnosis. C031 and C060 are different at the third character.
An official website of the United States government
Home
